Hainan Haiyao (000566): the new generation of cochlear implants has been further enriched.
Comments on Hainan Haiyao (000566) semi-annual report: two-vote system affects short-term performance and actively promotes business transformation
KuaiBao of Hainan Marine Pharmaceutical (000566) Co., Ltd.: the proposed acquisition of Qili Pharmaceutical has remarkable synergy and multi-line layout of the company's business.
Hainan Marine Pharmaceutical (000566) first coverage report: merger and acquisition of Qili Pharmaceutical to achieve business coordination, deep layout and innovative drug research and development
Hainan Haiyao (000566) follow-up comments: pre-increase in the performance of the China report
Deepin* Company* Hainan Haiyao (000566) Review: The majority shareholders' premium offer to buy shows confidence in the company's development
[Huarong Securities] Hainan Haiyao follow-up comments: the actual controller offers to purchase, full of confidence
Hainan Haiyao (000566) follow-up comments: the actual controller's offer is full of confidence.
Depth * Company * Hainan Marine Medicine (000566) comments: flufenidone has been approved in clinical trials and is optimistic about the company's long-term development.
[bank of China International Securities] Hainan Haiyao: flufenidone has been approved in clinical trials and is optimistic about the long-term development of the company.
【天风证券】海南海药:定增完成,翻开发展新篇章
海南海药(000566)点评:定增完成 翻开发展新篇章
海南海药(000566):业绩保持平稳 定增开启互联网医疗新阶段
海南海药(000566)中报点评:产业链布局基本成型 三大板块协同推进
【国泰君安】海南海药2016年中报点评:产业链布局基本成型,三大板块协同推进
海南海药(000566)点评:发力远程医疗 大健康平台蓄势待发
海南海药(000566)年报点评:业绩较快增长 继续耕耘大健康产业
【华泰证券】海南海药:业绩较快增长,继续耕耘大健康产业
海南海药(000566)点评:定增方案调整 大股东高比例认购
【西南证券】海南海药:定增方案调整,大股东高比例认购